In the general population and in heart disease, pulmonary hypertension (PH) is a strong and independent risk factor for mortality and adverse cardiovascular outcomes. We performed a systematic review and meta-analysis of longitudinal cohort studies of individuals with chronic kidney disease (CKD) of any-stage (also including end-stage kidney disease and kidney transplantation) stratified according to presence/absence of PH. Eighteen eligible studies (10 740 participants) were retrieved. PH had an overall pooled prevalence of 33% (95% CI 28-42) and portended a higher risk of all-cause mortality (RR 2.08; 1.06-4.08), cardiovascular mortality (RR 3.77; 2.46-5.78) and non-fatal cardiovascular events (RR 1.60; 1.28-1.99). PH is highly prevalent in CKD and end-stage kidney disease and may represent a novel factor for mortality and cardiovascular risk stratification, particularly in selected sub-categories. Future high-quality research is required to confirm the need for clinical attention on PH in the CKD setting.
Keywords: Cardiovascular events; Chronic kidney disease; End-stage kidney disease; Mortality; Pulmonary hypertension.
© 2018 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.